Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Missouri-Columbia

About this trial

During this pilot study, the investigators will examine the effects of whole-body electrical muscle stimulation exercise (WB-EMS Exercise) on neuromuscular junction (NMJ) transmission and fatigability in adults with Generalized Myasthenia Gravis (gMG). The investigators will also test whether a relationship exists between NMJ transmission dysfunction and fatigability in gMG, which has long been presumed but never directly assessed. Participants will undergo clinical and electrophysiologic testing before and after the WB-EMS Exercise intervention. The WB-EMS Exercise intervention will be delivered 2 times per week for 4 weeks. Long-term follow up is optional. The hypotheses are (a) that the WB-EMS exercise will improve fatigability and NMJ transmission, and (b) that NMJ transmission dysfunction is related to fatigability.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 18 or older

Diagnosed with Generalized Myasthenia Gravis (gMG) via seropositive test for acetylcholine receptor (AChR) antibodies or seronegative test with clinical symptoms consistent with gMG

On stable MG therapy for at least 1 month

Ability to stand for approximately 15 minutes continuously with or without an assistive device (i.e. the length of time to stand to take a shower, complete meal preparation, wait in line at the bank, etc.)

Disqualifiers

Concurrent participation in another interventional research study

Unable to tolerate 15 minutes of continuous standing with or without an assistive device

Regular participation in strength training (2x per week or more over the past 6 months)

Score of 0 (None) on all "arm outstretched" and "leg outstretched" items of the QMG

Trial design

Design model

Single group

Treatments tested in this trial

  • Whole-body Electrical Muscle Stimulation Exercise

    Device

    This is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs using an iPad App. The stimulation suit (fitted shorts/shirt, vest, leg straps, arm straps) will be donned with the assistance of trained research personnel. Muscle groups stimulated include biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings. The stimulation level of each individual muscle group can be tailored to participant responses and tolerance (i.e. stimulation of the quadriceps and biceps can occur at different settings). While the participant is following along with the video, a qualified health care professional will be monitoring and adjusting the stimulation levels based on participant responses; rate of perceived exertion will also be monitored to ensure safe moderate intensity levels are maintained.

Treatment groups

16 Participants
are divided into 1 treatment group
Group A: Whole-body Electrical Muscle Stimulation (WB-EMS) ExerciseExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Mean change from baseline in single fiber electromyography (SFEMG) jitter

Single fiber electromyography (SFEMG) jitter is a measure of neuromuscular junction transmission variability; a small needle will be inserted into one of the quadriceps muscles to obtain the measurement

Time frame
Measured within 3 days of starting the intervention and within 3 days of completing the intervention
2

Mean change from baseline in the linear change in performance during the six-minute walk test (6MWT)

Six-minute Walk Test (6MWT) is a measure of endurance and muscle fatigability; participants will walk as far as they can in 6 minutes

Time frame
Measured within 3 days of starting the intervention and within 3 days of completing the intervention
3

Mean change from baseline in the linear change in performance during the arm movement test (AMT)

Arm Movement Test (AMT) is a measure of upper extremity muscle fatigability; participants will move their arm back and forth between 2 targets as many times as they can in 90 seconds

Time frame
Measured within 3 days of starting the intervention and within 3 days of completing the intervention

Secondary outcomes

1

Mean change from baseline in the quantitative myasthenia gravis (QMG) score

Quantitative Myasthenia Gravis (QMG) is a measure of overall disease severity; items include eye movements, swallowing, speaking, breathing test, grip strength, and neck/arm/leg endurance. Thirteen items will be rated on a scale of 0-3 where higher scores indicated greater disease severity.

Time frame
Measured within 3 days of starting the intervention and within 3 days of completing the intervention
2

Mean change from baseline in motor unit firing rates of the vastus lateralis using decomposition electromyography (dEMG)

Decomposition electromyography (dEMG) is a measurement of motor unit activity; a surface electrode will be placed over the vastus lateralis in the thigh and participants will be asked to activate that muscle

Time frame
Measured within 3 days of starting the intervention and within 3 days of completing the intervention
3

Mean change from baseline in motor unit firing rates of the middle deltoid using decomposition electromyography (dEMG)

Decomposition electromyography (dEMG) is a measurement of motor unit activity; a surface electrode will be placed over the middle deltoid in the shoulder and participants will be asked to activate that muscle

Time frame
Measured within 3 days of starting the intervention and within 3 days of completing the intervention
4

Mean change from baseline in fatigue severity scale (FSS)

Fatigue Severity Scale (FSS) is a patient-reported outcome measure assessing the impact of perceived fatigue on a person's life over the prior 7-day period. Nine items are rated on a scale of 1-7 where higher scores indicate more impact of perceived fatigue.

Time frame
Measured within 3 days of starting the intervention and within 3 days of completing the intervention

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Missouri-Columbia

Lead sponsor

University of Kansas Medical Center

Collaborator